<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="32395">Arachidonate</z:chebi> lipoxygenase (ALOX) enzymes metabolize <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> to generate potent <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> and play an important role in <z:mp ids='MP_0001845'>inflammation</z:mp>-associated diseases </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated associations between <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk and polymorphisms in ALOX5, FLAP, ALOX12, and ALOX15, and their interactions with <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drug</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) use </plain></SENT>
<SENT sid="2" pm="."><plain>We genotyped fifty tagSNPs, one candidate SNP, and two functional promoter variable nucleotide tandem repeat (VNTR) polymorphisms in three US population-based case-control studies of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (1,424 cases/1,780 controls), <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> (583 cases/775 controls), and colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> (485 cases/578 controls) </plain></SENT>
<SENT sid="3" pm="."><plain>Individuals with variant genotypes of the ALOX5 VNTR had a decreased risk of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, with the strongest association seen for individuals with one or more alleles of &gt;5 repeats (<z:mp ids='MP_0002169'>wild type</z:mp> = 5, OR&gt;5/≥5 = 0.42, 95% CI 0.20-0.92; P = 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>Four SNPs in FLAP (rs17239025), ALOX12 (rs2073438), and ALOX15 (rs4796535 and rs2619112) were associated with <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> risk at P ≤ 0.05 </plain></SENT>
<SENT sid="5" pm="."><plain>One SNP in FLAP (rs12429692) was associated with <z:mpath ids='MPATH_270'>adenoma</z:mpath> risk </plain></SENT>
<SENT sid="6" pm="."><plain>A false discovery rate (FDR) was applied to account for false positives due to multiple testing; the ALOX15 associations were noteworthy at 25% FDR </plain></SENT>
<SENT sid="7" pm="."><plain>Colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> risk appeared to be modified by <z:chebi fb="1" ids="35475">NSAID</z:chebi> use in individuals with variant alleles in FLAP and ALOX15 </plain></SENT>
<SENT sid="8" pm="."><plain>One noteworthy interaction (25% FDR) was observed for <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Genetic variability in ALOXs may affect risk of colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, particularly for <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Additionally, genetic variability in FLAP and ALOX15 may modify the protective effect of <z:chebi fb="1" ids="35475">NSAID</z:chebi> use against colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo>. © 2013 Wiley Periodicals, Inc </plain></SENT>
</text></document>